alopecia

Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 for the Treatment of Alopecia Areata

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.

FDA Breakthrough Therapy Designation is intended to expedite the development and review of medicines aimed at treating a serious or life-threatening disease where there is preliminary clinical evidence that the investigational therapy may offer a substantial improvement over existing therapies.

“We are pleased that the FDA has recognized the therapeutic potential of CTP-543 as a new treatment in development for alopecia areata,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Our goal is to bring this potential new therapy to patients as quickly as possible. We look forward to working closely with the FDA to expedite the development of CTP-543.”

FDA Breakthrough Therapy Designation for CTP-543 is supported by positive data from a Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.

In September 2019, Concert reported that patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by Severity of Alopecia Tool (SALT).

The 8 mg twice daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving a SALT score of 20 or less at 24 weeks, which is the primary efficacy endpoint that Concert intends to utilize in its pivotal registration studies. Treatment with CTP-543 was generally well-tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

As the next step in the CTP-543 clinical program, Concert intends to initiate its Phase 3 clinical program in the fourth quarter of 2020.

CTP-543 has also received Fast Track designation in the U.S. for the treatment of alopecia areata.

Additional information about the CTP-543 Phase 2 results is available in the Scientific Presentations section of the Company’s website.

About the Phase 2 Trial Design of CTP-543 in Alopecia Areata

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.

A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata. The Company intends to advance CTP-543 into Phase 3 evaluation in the fourth quarter of 2020.

c Alopecia areata may affect approximately 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Source

Recent Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 for the Treatment of Alopecia Areata

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

There are currently no drugs approved by the FDA for the treatment of alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.

FDA Breakthrough Therapy Designation is intended to expedite the development and review of medicines aimed at treating a serious or life-threatening disease where there is preliminary clinical evidence that the investigational therapy may offer a substantial improvement over existing therapies.

“We are pleased that the FDA has recognized the therapeutic potential of CTP-543 as a new treatment in development for alopecia areata,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Our goal is to bring this potential new therapy to patients as quickly as possible. We look forward to working closely with the FDA to expedite the development of CTP-543.”

FDA Breakthrough Therapy Designation for CTP-543 is supported by positive data from a Phase 2 clinical trial in patients with moderate-to-severe alopecia areata.

In September 2019, Concert reported that patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by Severity of Alopecia Tool (SALT).

The 8 mg twice daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving a SALT score of 20 or less at 24 weeks, which is the primary efficacy endpoint that Concert intends to utilize in its pivotal registration studies. Treatment with CTP-543 was generally well-tolerated, with one serious adverse event reported in the 12 mg dose group where the patient was able to complete the trial after a brief dose interruption.

As the next step in the CTP-543 clinical program, Concert intends to initiate its Phase 3 clinical program in the fourth quarter of 2020.

CTP-543 has also received Fast Track designation in the U.S. for the treatment of alopecia areata.

Additional information about the CTP-543 Phase 2 results is available in the Scientific Presentations section of the Company’s website.

About the Phase 2 Trial Design of CTP-543 in Alopecia Areata

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.

A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata. The Company intends to advance CTP-543 into Phase 3 evaluation in the fourth quarter of 2020.

c Alopecia areata may affect approximately 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata

Source

Recent Posts

Trial of HST 001 for Androgenic Alopecia

Trial of HST 001 for Androgenic Alopecia

Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia

Histogen Inc, a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.

This blinded, randomized, placebo-controlled, single-site study will enrol 36 subjects with male pattern hair loss using a 2:1 randomization HST 001 to placebo. It is designed to assess the safety and tolerability of HST 001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.

“The initiation of this clinical trial is a critical milestone for Histogen following the completion of our merger and listing on the Nasdaq Capital Market last week,” said Richard Pascoe, Chief Executive Officer of Histogen. “HST 001 is a potentially transformative approach to treating androgenic alopecia given that existing therapies focus on reducing hair loss, while HST 001 has the potential to stimulate new long-lasting hair growth.”

Building on prior clinical experience with HST 001, the Phase 1b/2a study will be the first company-sponsored trial to include a third dosing time point, with dosing taking place at week 0, week 6 and week 12.

At each treatment timepoint, subjects will receive 20 injections focused on temporal recession and vertex scalp areas, the most common regions of hair loss in men with androgenic alopecia.

Top-line data is anticipated to be available in the fourth quarter of 2020.

About HST 001

HST 001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.

HSC is manufactured to enrich for growth factors including KGF, VEGF, and follistatin, which are involved in signalling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen

Histogen is a regenerative medicine company developing patented technologies that replace and regenerates tissues in the body. The company’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address underserved, multi-billion US dollar global markets. For more information, please visit www.histogen.com.

Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia

Source

Previous Posts

Global Hair Transplant System Market Report

Global Hair Transplant Services Market

Global Hair Transplant Services Market

Global Hair Transplant Services Market is accounted for xx USD million in 2019 and is expected to reach xx USD million by 2026 growing at a CAGR of xx% during the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global Hair Transplant Services market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026.

Hair Transplant Services Market report covers size, share and forecast (value and volume) by regions, top players, product types and applications, with historical data along with forecast from 2019 to 2026; The report covers an in depth description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter’s Five Forces Analysis.

By geography, this market has been segregated into five regions with revenue and growth rate of Hair Transplant Services from 2013 to 2026,

• North America  (U.S., Canada, Mexico)
• Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
• Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
• Latin America (Brazil, Rest of L.A.)
• Middle East And Africa(Turkey, GCC, Rest of Middle East)

The major players operating into Hair Transplant Services Market include:

Bernstein Medical
Bosley
Medicamat
Hair Transplants of Florida
Cole Instruments
Limmer Hair Transplant Center
getFUE Hair Clinics
Hair Transplant Center
The Hairline Clinic
Capillus
LaserCap
Solta Medical
PhotoMedex

This report segments the Global Hair Transplant Services Market as follows:

Global Hair Transplant Services Market: Type Segment Analysis
Follicular Unit Transplantation (FUT)
Follicular Unit Extraction (FUE)
Scalp Reduction

Global Hair Transplant Services Market: Application Segment Analysis

Hospitals
Specialized Clinics
Ambulatory Surgical Centers

There are 13 chapters to put on view for Hair Transplant Services Market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: Market competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Hair Transplant Services Research Findings and Conclusion, Appendix, methodology and data source

Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export have been determined using secondary sources and verified primary sources. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.

Industry Chain Analysis

Raw Material and Suppliers
Equipment and Suppliers
Manufacturing Process
Manufacturing Cost Structure
Manufacturing Plants Distribution Analysis

Global Hair Transplant Services Market

Source

Previous Posts

Alopecia Treatment Market

Global Androgenic Alopecia Drug Market Insights

Global Androgenic Alopecia Drug Market Insights, Forecast to 2025

In 2017, the global Androgenic Alopecia Drug market size was  million US$ and is forecast to  million US in 2025, growing at a CAGR of  from 2018. The objectives of this study are to define, segment, and project the size of the Androgenic Alopecia Drug market based on company, product type, application and key regions.

This report studies the global market size of Androgenic Alopecia Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Androgenic Alopecia Drug in these regions.

This research report categorizes the global Androgenic Alopecia Drug market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.

The various contributors involved in the value chain of Androgenic Alopecia Drug include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Androgenic Alopecia Drug include
Allergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

Market Size Split by Type
RK-023
Refagro
RCH-01
SM-04554
HYG-440
Others

Market Size Split by Application
Clinic
Hospital
Home Use

Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Androgenic Alopecia Drug market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Androgenic Alopecia Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Androgenic Alopecia Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Androgenic Alopecia Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Androgenic Alopecia Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Androgenic Alopecia Drug are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Androgenic Alopecia Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Androgenic Alopecia Drug Market Insights, Forecast to 2025

Source

Previous Posts

Alopecia Treatment Market Insights

Global Androgenic Alopecia Drug Market Report 2019

Global Androgenic Alopecia Drug Market Report 2019

With the slowdown in world economic growth, the Androgenic Alopecia Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Androgenic Alopecia Drug market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018.

Research analysts believe that in the next few years, Androgenic Alopecia Drug market size will be further expanded, we expect that by 2023, The market size of the Androgenic Alopecia Drug will reach XXX million $.

This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better.

This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Manufacturer Detail
Allergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)

Product Type Segmentation
RK-023
Refagro
RCH-01
SM-04554
HYG-440

Industry Segmentation
Clinic
Hospital
Home Use

Channel (Direct Sales, Distributor) Segmentation

Trend (2018-2023)

Product Type Detail

Downstream Consumer

Cost Structure

Conclusion

Global Androgenic Alopecia Drug Market Report 2019

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

CTP-543 Phase 2 Alopecia Areata

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

-Concert Pharmaceuticals today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking news session at the European Academy of Dermatology and Venereology (EADV) Annual Congress to be held October 9– 13, 2019 in Madrid, Spain.

The details of the presentation are as follows:

Title: CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate-to-severe alopecia areata
Date and Time: Saturday, October 12, 2019 at 9:15 – 9:30 GMT
Session: Late-Breaking News Session
Room: Hall 10 Dali

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

Source

Previous Posts

Treatment of alopecia universalis

Five updates for Alopecia Areata Awareness Month

Five updates for Alopecia Areata Awareness Month

Alopecia areata affects up to 6.8 million people in the U.S. and carries a 2.1% lifetime risk, according to the National Alopecia Areata Foundation. The foundation has dubbed September “Alopecia Areata Awareness Month” to increase awareness, spread empowerment and raise funds for research into this polygenic autoimmune disease.

In honor of this awareness month, Healio Dermatology has compiled the following recent articles that explore treatment pathways and the latest research in alopecia areata.

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Inflammation plays a key role in male and female pattern hair loss, Neal Walker, DO, president and CEO of Aclaris Therapeutics, said in an interview with Healio Dermatology regarding results from a phase 2 open-label clinical trial in patients with androgenetic alopecia. Read more

Top-line results show efficacy of LED cap for androgenetic alopecia

Data from a randomized, double-blind, placebo-controlled trial demonstrated that Revian Red – an LED cap for the treatment of androgenic alopecia — may stop hair loss and subsequently grow new hair, according to a press release. Read more

Systemic therapy with JAK inhibitors may be future of alopecia areata treatment

There are no reliable, effective therapies for severe disease in alopecia areata; however, systemically administered Janus kinase inhibitors hold potential for the treatment of the condition, as well as vitiligo, according to a presenter at the AAD Summer Meeting. Read more

Hidradenitis suppurativa increases risk for alopecia

In a study investigating the relationship between hidradenitis suppurativa and alopecia areata in a U.S. sample, those with hidradenitis suppurativa had a significantly higher risk for alopecia of any type and also lichen planopilaris. Read more

Cyclosporin ‘moderately effective’ at inducing remission of alopecia areata

Adults with moderate to severe alopecia areata treated with cyclosporin had a greater reduction in Severity of Alopecia Tool score over time when compared with a placebo group in a randomized trial. Read more

Alopecia Areata Awareness Month

Source

Previous Posts

Alopecia Treatment Market

Global Androgenic Alopecia Drug Market

Global Androgenic Alopecia Drug Market By Product Type (RK-023, Refagro) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 – 2026

Global Androgenic Alopecia Drug Market is accounted for xx USD million in 2019 and is expected to reach xx USD million by 2026 growing at a CAGR of xx% during the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global Androgenic Alopecia Drug market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026.

Androgenic Alopecia Drug Market report covers size, share and forecast (value and volume) by regions, top players, product types and applications, with historical data along with forecast from 2019 to 2026; The report covers an in depth description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter’s Five Forces Analysis.

By geography, this market has been segregated into five regions with revenue and growth rate of Androgenic Alopecia Drug from 2013 to 2026,

• North America  (U.S., Canada, Mexico)
• Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
• Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
• Latin America (Brazil, Rest of L.A.)
• Middle East And Africa(Turkey, GCC, Rest of Middle East)

The major players operating into Androgenic Alopecia Drug Market include:

Histogen kick starts clinical trial for female hair lossAllergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

This report segments the Global Androgenic Alopecia Drug Market as follows:

Global Androgenic Alopecia Drug Market: Type Segment Analysis
RK-023
Refagro
RCH-01
SM-04554
HYG-440
Others

Global Androgenic Alopecia Drug Market: Application Segment Analysis
Clinic
Hospital
Home Use

There are 13 chapters to put on view for Androgenic Alopecia Drug Market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: Market competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Androgenic Alopecia Drug Research Findings and Conclusion, Appendix, methodology and data source

Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export have been determined using secondary sources and verified primary sources. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.

Industry Chain Analysis

Raw Material and Suppliers
Equipment and Suppliers
Manufacturing Process
Manufacturing Cost Structure
Manufacturing Plants Distribution Analysis

Available Customizations

We can also provide customized report as per company’s specific needs. We can also provide the customized separate regional or country-level reports, for the specific region as per client requirement.

Global Androgenic Alopecia Drug Market

Source

Previous Posts

Fast Shampoo

Hair Styling Products Market

Hair Styling Products Market: Global Industry Analysis 2013-2017

This report on the hair styling products market provides the forecast and analysis of the global hair styling products market. It provides analysis on the basis of historical data and forecast from 2017 to 2027 in terms of revenue (US$ Mn). The hair styling products report reveals the market dynamics in seven geographic segments along with market analysis for the current and future scenario. In addition, it includes drivers, restraints and recent trends of the hair styling products market.

The hair styling products market report also comprises opportunities for the manufacturers of hair styling products and highlights the value chain analysis in detail. The study demonstrates the market dynamics and trends across regions that are expected to influence the current status and future prospects of the hair styling products market.

The report studies the global hair styling product market period 2018–2027. The prime objective of this report is to offer quantitative and qualitative insights and the study key market trends pertaining to the global hair styling products market that gradually help transform businesses.

The hair styling products market numbers have been assessed by carefully scrutinizing the hair styling products spending of countries in all the seven key regions for the current year, as well as the historical performance of the market. Market size and forecast for each segment in the hair styling products market has been provided in the context of regional markets.

All the segmentation of the hair styling products market has been considered after appropriate secondary research and revalidation of the data obtained through interviews with key thought leaders and industry experts. The market has been forecast based on constant currency rates. The report includes the revenue generated from sales of hair styling products across all regional economies.

The report begins with an executive summary intended to provide a clear perspective about the hair styling products market to the reader. It is then followed by an overview of the hair styling products market and provides the definition of the market along with an analysis about the drivers, restraints, opportunities and key trends in the hairstyling products market. The sections that follow includes the analysis of the global hair styling products market by product type, source, end use, sales channel and a country-level analysis.

On the basis of product type, the global hair styling products market is segmented into hair gel, hair spray, styling creams & waxes, hair mousse and other types of hair styling products. The global hair styling products market is further segmented on the basis of end use. The potential end users are household, salon & spa and the fashion industry.

The global hair styling products market is again segmented on the basis of gender i.e. male, female and unisex. On the basis of sales channel, the global hair styling products market is segmented into wholesaler/distributor, supermarket/hypermarket, convenience store, specialty store and online store.

All the above sections evaluate the hair styling products market on the basis of various factors affecting the market, which cover the present scenario as well as the future prospects.

For market data analysis, the report considers 2017 as the base year, with market numbers estimated for 2018 and forecast made for 2018–2027. All the segmentation of the hair styling products market has been considered after appropriate secondary research and revalidation of the data obtained through interviews with key thought leaders in the industry. The hair styling products market has been forecast based on constant currency rates.

The next section of the hair styling products report highlights the market by region and provides the market outlook for 2018–2027. The study investigates the regional Year-on-Year (Y-o-Y) growth of the hair styling products market. Key regions assessed in this report include North America, Latin America, Europe, Asia Pacific Excluding Japan, Middle East & Africa and Japan. The report evaluates the present scenario and growth prospects of the regional market for 2018–2027.

The hair styling products market numbers have been assessed based on the sales and the weighted average pricing of hair styling products by nature and product type. The aggregate revenue is derived through the weighted average country pricing trends. The hair styling products market size and forecast for each segment have been provided in the context of countries. The hair styling products market has been analysed based on the expected demand and current spending scenario.

The prices considered for the calculation of revenue are the average country prices obtained through primary quotes from numerous regional manufacturers, suppliers and distributors of hair styling products. All the key product types have been considered on the basis of secondary sources, i.e. OECD, UN data and feedback from primary respondents. Country-wise demand patterns have been considered while estimating the consumption of hair styling products across various regions.

Hair styling products market numbers for all the regions by product type, base material, end use and distribution channel have been derived using the bottom-up approach, which is cumulative of each country’s demand.

The company-level hair styling products market share has been derived on the basis of the revenues reported by key manufacturers. The hair styling products market has been forecast based on constant currency rates.

Given the characteristics of the market, we have triangulated the outcome on the basis of three different types of analysis: based on supply side, demand side analysis for hair styling products and the impact of macro-economic factors on the hair styling products market.

In addition, it is imperative to note that, in a fluctuating global economy, we not only conduct market forecasts in terms of Compound Annual Growth Rate (CAGR), but also analyse the market based on key parameters, such as Y-o-Y growth rates, to understand the predictability of the hair styling products market and identify the right opportunities for players.

The market segments for the global hair styling products market have been analysed in terms of Basis Point Share (BPS) to understand the relative contributions of each segment to market growth. This detailed level of information is important for identifying various key trends in the hair styling products market.

Another key feature of this report is the analysis the market in terms of absolute dollar opportunity represented by the sales of hair styling products. Absolute dollar opportunity is critical for evaluating the scope of opportunity that a provider can look to achieve as well as to identify the lucrative segments.

he overall absolute dollar opportunity represented by the hair styling products market is mentioned in the report. To understand key growth segments in terms of growth and adoption for hair styling products in the global market, XploreMR has developed the market ‘Attractiveness Index.’ The resulting index is expected to help providers identify the real market opportunities.

A number of primary and secondary sources were referred during the course of the study. Some of the secondary sources include IMF, World Bank, Hoovers, Factiva, annual reports of companies and government associations & publications.

In the final section of the report on the hair styling products market, a ‘dashboard view’ of the companies has been provided to compare the current industrial scenario and their contribution in the overall hair styling products market.

Moreover, it is primarily designed to provide clients an objective and detailed comparative assessment of the key providers specific to a segment in the hair styling products market.

Report audiences can gain segment-specific manufacturer insights to identify and evaluate the key competitors in the hair styling products market. Detailed profiles of companies are also included in the report to evaluate their strategies, key product offerings and recent developments.

Some of the key players of the global hair styling products market are Procter & Gamble, L’Oreal, Unilever plc, Shiseido Company, Amorepacific Corporation, Flora Ltd., Kao Corporation, Henkel AG & Company, Godefroy Manufacturing Company, Swallowfield plc, Shu Uemura Art of Hair, Vogue International LLC, CURLS(R), LLC, Ouai haircare, Redken, Scental Pacific, Delta Laboratories Pty Ltd., Natrocare Laboratories, Mizani and Mielle Organics LLC.

Hair Styling Products Market: Global Industry Analysis 2013-2017

Source

Previous Posts

GKhair was Bright and Beautiful at Premiere Orlando 2019

GKhair was Bright and Beautiful at Premiere Orlando 2019

GKhair was Bright and Beautiful at Premiere Orlando 2019

Premiere Orlando was held from 2nd – 3rd June this year and GKhair participated in full swing, bringing the newest in technique and technology to stage.

With a resolve for imparting education, the brand has always been on the front line at similar events where artists from all over the world gather to learn and educate.

This year, many GKhair artists presented their skills on stage and attracted a large crowd of onlookers.

Multiple techniques like hair taming, styling, cuts and colors were displayed during the two days of exhibition at the event. Consequently, the GKhair stage was crowded throughout the event that lasted for two days.

The main focus at the GKhair stage was a new innovative technique of hair color – Bamboo Color – recently developed by Federico Longo from Italy. Bamboo Color has been inspired by the bamboo shoots to achieve customized yet natural end results. The technique embodies coloring and lightening hair at the same time.

Apart from that, several other educators also remained active at the stage, where they carried out live transformations sharing their knowledge and skills regarding coloring, styling, and hair taming.

GKhair’s brand new Flat Irons – One Control Titanium Flat Iron, D700 Titanium Flat Iron, and Easy Control Titanium Flat Iron – were also featured at the stage.
These irons have been receiving amazing feedback since they made it to the GKhair product line.

Besides, famous Venezuelan hair artist, Andrés Aragòn also visited the GKhair stage and took keen interest in the unique display of talent. It was very heartening for the GKhair team to see hair artists and partners coming in from different parts of the world to show their love and appreciation for the efforts of the brand to empower the hair industry.

Find more lively details about the event, here.

About GKhair

Operating in more than 75 countries, GKhair is a US-based haircare brand that has millions of clients across the world.

GKhair was Bright and Beautiful at Premiere Orlando 2019

 

Source

Previous Posts